Inverness Medical, Quidel lock horns over patents:
This article was originally published in Clinica
POC diagnostics firm Quidel has filed suit against Inverness Medical Innovations, accusing Inverness and Applied Biotech, which it acquired from Apogent last year, of patent infringement. The suit, relating to lateral-flow technology, was filed in a US district court in California. The week before, Inverness, of Waltham, Massachusetts, filed suit against Quidel in a court in Dusseldorf, Germany, alleging infringement of two Inverness-owned European patents. San Diego, California-based Quidel says it will "defend that action vigorously".
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.